Complex generics are becoming the most widely manufactured pharmaceutical product, giving cost-effective alternatives at the same time pose challenges to various stakeholders. In this study, we are focused on the market growth barriers and facilitators in the top two complex generic markets. A mixed-method market dynamic study was employed. 4Ps analysis (Product, price, place, and promotion) study was conducted quantitatively to know the market share and trends of complex generics in the United States and India. Strength, weakness, opportunities, and challenges analysis is employed to analyze internal and external strengths to develop strategic planning and management techniques to achieve market success. Data were collected from regulatory agency reports, online registered pharmacy websites, government retail pharmacy websites, IQVIA databases, and published literatures. Nonbiologic complex oral API products were seen to be more in US and Indian markets. Chemotherapeutic agents (capsule, tablets, and injectables) and respiratory agents (aerosols) are the leading complex generics. Price study shows an average 45%–60% reduction in selling price compared to innovator drugs. Promotional activities fully depend on the physician. The increasing demand for complex generics, driven by their affordability compared to name-brand equivalents, is highlighted in the strength section. The weakness section involves the regulatory obstacles, such as potential delays in drug approval and complexity of the manufacturing process, such as difficulty in establishing bioequivalence (BE), increased production costs, and so on. The opportunities section looks at ways to grow the industry, such as developing strategic relationships with new technologies like continuous manufacturing procedures and model-informed formulation development. Finally, the challenges, such as stringent BE requirements and a lack of regulatory guidelines, which delay the approval and market entry of complex generics, are highlighted. The evolving complex generic market requires a well-defined technology-driven approach for substantial growth. This article highlights the dynamic nature of the complex generics market and provides stakeholders with helpful information for making strategic decisions to effectively navigate the complex nature of this particular market sector and achieve long-term growth.
Sreedevi A, Ramesh VL, Janodia MD, Kumar P, Ligade VS. Exploring the market dynamics of complex generics in United States and India. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2025.v15.i12.15
1. Rashidian A, Omidvari H, Vali Y, Sturm H, Oxman AD. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev. 2015;2015(8):CD006731. https://doi.org/10.1002/14651858.CD006731.pub2
2. Kirking DM, Ascione FJ, Gaither CA, Welage LS. Economics and structure of the generic pharmaceutical industry. J Am Pharm Assoc. 2001;41(4):578-84. https://doi.org/10.1016/S1086-5802(16)31282-7
3. Duncan A, Viswanadh K, Baudino S, Donelan R, Lassoff P, Rhoades RA, et al. Complex generics: charting a new path [Internet]. 2016 [cited 2023 Jul 11]. Available from: https://www.iqvia.com/library/white-papers/complex-generics-charting-a-new-path
4. Demina NB, Bakhrushina EO, Anurova MN, Merkushova AG, Pomytkina MV, Rastopchina OV, et al. Complex generics as a trend of modern pharmaceutical development. Int J Appl Pharm. 2024;16:71-7.
5. Businesswire. Super generics market, 2035-ResearchAndMarkets.Com; 2024 [cited 2024 Apr 28]. Available from: https://www.businesswire.com/news/home/20240606270663/en/Super-Generics-Market-2035---ResearchAndMarkets.com
6. Roots analysis. Super generics market size & share revenue growth 2035. 2024 [cited 2024 Apr 28]. Available from: https://www.rootsanalysis.com/reports/super-generics-market/275.html
7. Lunawat S, Bhat K. Complex generic products: insight of current regulatory frameworks in US, EU and Canada and the need of harmonisation. Ther Innov Regul Sci. 2020;54(5):991-1000. https://doi.org/10.1007/s43441-020-00114-6
8. FDA. Complex generics news. Center for drug evaluation and research. 2023 [cited 2024 Aug 12]. Available from: https://www.fda.gov/drugs/generic-drugs/complex-generics-news
9. Skyquestt. Specialty generics market size, growth & trends report 2031. 2024 [cited 2024 Apr 28]. Available from: https://www.skyquestt.com/report/specialty-generics-market
10. Teva blog. Complex generics: facts, figures and who they benefit. 2024 [cited 2024 Apr 20]. Available from: https://www.tevapharm.com/news-and-media/feature-stories/what-are-complex-generics/
11. Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines. Sandoz [Internet]. [cited 2024 Aug 12]. Available from: https://www.sandoz.com/sandoz-completes-acquisition-aspens-japanese-operations-strengthening-its-position-worlds-third/
12. Building sustainable access to medicine. 2022 Viatris Sustainability Report [Internet]. [cited 2024 Aug 12]. Available from: https://www.viatris.com.tr//media/project/common/viatris/csrpromo/pdfs/2023_345_2023csrreport_revised.pdf
13. Specialty generics market share | Statistics report, 2032 | The Brainy Insights [Internet]. [cited 2024 Apr 8]. Available from: https://www.thebrainyinsights.com/report/specialty-generics-market-13722#summary
14. Penner SJ, Allen CM, Bralye WE, Macedo MA, Porter AD, Rothhammer HN, et al. Economics of health care. In: Penner SJ, editor. Economics and financial management for nurses and nurse leaders [Internet]. New York, NY: Springer Publishing Company; 2016. pp 1-26. Available from: https://connect.springerpub.com/content/book/978-0-8261-6002-7/part/part01/chapter/ch01
15. Skyquestt. Global specialty generics market size and forecast to 2030. 2024 [cited 2024 Apr 28]. Available from: https://www.skyquestt.com/report/specialty-generics-market
16. Frank RG, McGuire TG, Nason I. The evolution of supply and demand in markets for generic drugs. Milbank Q. 2021;99(3):828-52. https://doi.org/10.1111/1468-0009.12517
17. Francois C, Gawlik G, Mestre-Ferrandiz J, Pana A, Perelman J, Yfantopoulos J, et al. New pricing models for generic medicines to ensure long-term sustainable competition in Europe. Front Pharmacol. 2023;14:1200641. https://doi.org/10.3389/fphar.2023.1200641
18. Moosapour H, Saeidifard F, Aalaa M, Soltani A, Larijani B. The rationale behind systematic reviews in clinical medicine: a conceptual framework. J Diabetes Metab Disord. 2021;20(1):919-29. https://doi.org/10.1007/s40200-021-00773-8
19. Mostafa S, Mohammad MA, Ebrahim J. Policies and practices catalyzing the use of generic medicines: a systematic search and review. Ethiop J Health Sci. 2021;31(1):167-78. https://doi.org/10.4314/ejhs.v31i1.24
20. Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open. 2015;5(12):e008915. https://doi.org/10.1136/bmjopen-2015-008915
21. Twin A. Investopedia. The 4 Ps of marketing: what they are & how to use them successfully. [cited 2024 Aug 21]. Available from: https://www.investopedia.com/terms/f/four-ps.asp
22. GoodRx. Prescription prices, coupons & pharmacy information. 2024 [cited 2024 Aug 12]. Available from: https://www.goodrx.com
23. National Library of Medicine. MedlinePlus [Internet]. Bethesda, MD: National Library of Medicine (US) [cited 2024 Aug 12]. Available from: https://medlineplus.gov/
24. CIMS. Search drug information, interactions, images, dosage & side effects. CIMS India; 2024 [cited 2024 Aug 12]. Available from: https://www.mims.com/india
25. 1 mg. 1 mg editorial policy and processes. Tata 1 mg. 2024 [cited 2024 Apr 20]. Available from: https://www.1mg.com/editorial-policy-processes
26. Janaushadhi. Pharmaceuticals & Medical Devices Bureau of India; 2024 [cited 2024 Aug 12]. Available from: https://janaushadhi.gov.in/
27. SK-Pharma. Affordable care redefined: the emerging impact of complex generics on global health. SK-Pharm blog; 2024 [cited 2024 Apr 24]. Available from: https://sk-pharma.com/media/affordable-care-redefined-the-emerging-impact-of-complex-generics-on-global-health/
28. Viatris. Our story. Viatris Homepage; 2024 [cited 2024 Apr 28]. Available from: https://www.viatris.com/en/about-us/our-story
29. Avhad PA, Chalikwar SS, Bhairav BA. A comprehensive review on complex generics. Medicine 2022;105:129-35. https://doi.org/10.31489/2022bmg1/129-135
30. Perappadan BS. Generic drugs to treat four rare diseases launched. The Hindu [Internet]; 2023 [cited 2024 Jul 8]. Available from: https://www.thehindu.com/sci-tech/health/four-generic-made-in- india-drugs-to-treat-rare-diseases-offer-relief-for-patients-more-in-pipeline/article67570839.ece
31. Manual of Policies and Procedures (MAPP) 5240.10. [Internet]. [cited 2024 Jul 8]. Available from: https://www.fda.gov/media/157675/download
32. IQVIA. US generics market - evolution of Indian players. Durham, NC: IQVIA [Internet]; 2019 [cited 2024 Jul 8]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/india/us-generics-market-evolution-of-indian-players.pdf
33. Super generics market size & share revenue growth 2035 [Internet]. [cited 2024 Apr 8]. Available from: https://www.rootsanalysis.com/reports/super-generics-market/275.html
34. Quality Matters. Complex generics: are global regulators addressing the needs? | Quality Matters | U.S. Pharmacopeia Blog; 2023 [cited 2024 Apr 12]. Available from: https://qualitymatters.usp.org/complex-generics-are-global-regulators-addressing-needs
35. FDA. Reducing the hurdles for complex generic drug development. FDA; 2022 [cited 2024 Apr 9]. Available from: https://www.fda.gov/news-events/fda-voices/reducing-hurdles-complex-generic-drug-development
36. Zhang L, Lionberger RA. Generics 2030: where are we heading in 2030 for generic drug science, research, and regulation? Clin Pharmacol Ther. 2020;107(6):1293-5. https://doi.org/10.1002/cpt.1742
37. Tan ML, Chandran S, Jereb R, Alam K, Bies R, Kozak D, et al. Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: a workshop summary report. CPT Pharmacometrics Syst Pharmacol. 2023;12(5):631-8. https://doi.org/10.1002/psp4.12952
38. Research C for DE and the center for research on complex generics. FDA [Internet]; 2024 [cited 2024 Apr 22]. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/center-research-complex-generics
39. Srivastava V, editor. Ch. 1, Peptide therapeutics: strategy and tactics for chemistry, manufacturing and controls. The Royal Society of Chemistry; 2019. pp 1-30. https://doi.org/10.1039/9781788016445
40. Outsourcing-pharma.com. Absorption systems: complex generics offer obstacles, opportunities. outsourcing-pharma.com; 2020 [cited 2024 Jul 9]. Available from: https://www.outsourcing-pharma.com/Article/2020/07/21/Complex-generic-drugs-provide-opportunities-and-obstacles
41. O’Brien MN, Jiang W Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144-58. https://doi.org/10.1016/j.jconrel.2021.06.017
42. Minghetti P, Musazzi UM, Casiraghi A, Rocco P. Old active ingredients in new medicinal products: is the regulatory path coherent with patients’ expectations? Drug Discov Today. 2020;25(8):1337-47. https://doi.org/10.1016/j.drudis.2020.05.013
43. Kapoor V, Kaushik D. A comparative study of regulatory prospects for drug-device combination products in major pharmaceutical jurisdictions. J Generic Med Bus J Generic Med Sect. 2013;10(2):86-96. https://doi.org/10.1177/1741134313515665
44. Bhatt M, Tank S, Shah J, Maheshwari D. Regulatory framework and disparities of complex generics in United States, European Union & Latin America. J Generic Med Bus J Generic Med Sect. 2023;19(3):130-40. https://doi.org/10.1177/17411343231194755
45. Patil S, Kumar S, Rao DM, Rewatkar K. Current regulatory framework and challenges for the approval of complex generics in the US and the EU. Curr Indian Sci. 2024;02:e2210299X269535. https://doi.org/10.2174/012210299X269535231203164108
46. Satheesh G, Sharma A, Puthean S, Ansil TPM, Jereena E, Raj Mishra S, et al. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India. Trop Med Int Health. 2020;25(12):1467-79. https://doi.org/10.1111/tmi.13494
47. Klein K, Borchard G, Shah VP, Flühmann B, McNeil SE, de Vlieger JSB. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Ann N Y Acad Sci. 2021;1502(1):5-13. https://doi.org/10.1111/nyas.14662
48. Super generics industry analysis in Europe [Internet]. [cited 2024 Jul 9]. Available from: https://www.futuremarketinsights.com/reports/super-generics-industry-analysis-in-europe
49. Dutta T, Ramachandran S. Growing complex injectable portfolio in the Indian generic industries. 2023. pp 25. Available from: https://www.pharmafocusasia.com/biopharma/growing-complex-injectable-portfolio.
50. Research C for DE and upcoming product-specific guidances for generic drug product development. FDA [Internet]; 2024 [cited 2024 Jul 10]. Available from: https://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific-guidances-generic-drug-product-development
51. Commissioner of the FDA. FDA Approves First Generic of a Commonly Used Albuterol Inhaler to Treat and Prevent Bronchospasm. FDA; 2020 [cited 2024 Jul 9]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-commonly-used-albuterol-inhaler-treat-and-prevent-bronchospasm
52. Sari SP, Putri IDA, Nursanti B. Cost-effectiveness analysis of ceftriaxone generic and patent in children with typhoid. Int J Appl Pharm. 2018;10:76-80. https://doi.org/10.22159/ijap.2018.v10s1.16
53. Brill A. Potential savings from accelerating US approval of complex generics [Internet]. 2021 [cited 2024 Jul 9]. Available from: https://accessiblemeds.org/sites/default/files/2021-02/Potential-Savings-Complex-Generics-Feb2021.pdf
54. Simulations Plus [Internet]. Public workshop summary report on fiscal year 2021 generic drug regulatory science initiatives: data analysis and model-based bioequivalence. 2020 [cited 2024 Jul 9]. Available from: https://www.simulations-plus.com/resource/public-workshop-summary-report-on-fiscal-year-2021-generic-drug-regulatory-science-initiatives-data-analysis-and-model-based-bioequivalence/
55. Complex generics: facts, figures and who they benefit [Internet]. 2024 [cited 2024 Jul 9]. Available from: https://www.tevapharm.com/news-and-media/feature-stories/what-are-complex-generics/
56. Pillsbury D. Certara. Model-informed formulation development: insights from a case study. 2023 [cited 2024 Jul 9]. Available from: https://www.certara.com/blog/model-informed-formulation-development-insights-from-a-case-study/
57. MarketWatch [Internet]. Super generics market, 2035 - ResearchAndMarkets.com. 2024 [cited 2024 Jul 9]. Available from: https://www.marketwatch.com/press-release/super-generics-market-2035-researchandmarkets-com-91836c65
58. Lionberger RA. Innovation for generic drugs: science and research under the generic drug user fee amendments of 2012. Clin Pharmacol Ther. 2019;105(4):878-85. https://doi.org/10.1002/cpt.1364
59. Andhariya, JV, Jog R, Shen J, Choi S, Wang Y, Zou Y, et al. In vitro-in vivo correlation of parenteral PLGA microspheres: effect of variable burst release. J Control Release. 2019;314:25-37. https://doi.org/10.1016/j.jconrel.2019.10.014
60. Committee for Medicinal Products for Human Use. Guideline on quality of transdermal patches. London, UK: Committee for Medicinal Products for Human Use (CHMP); 2014.
61. Lee SL, Saluja B, García-Arieta A, Santos GM, Li Y, Lu S, et al. Regulatory considerations for approval of generic inhalation drug products in the US, EU, Brazil, China, and India. AAPS J. 2015;17(5):1285-304. https://doi.org/10.1208/s12248-015-9787-8
62. Alam K. Mechanistic modeling of complex injectables: recommendations to navigate regulatory challenges. CDER | US FDA [Internet]; 2022 [cited 2024 Jul 9]. Available from: https://www.fda.gov/media/166586/download
63. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282-95. https://doi.org/10.1208/s12248-012-9339-4
64. Prasad V, Pooja K. Complex generics: opportunities & challenges. Int J Drug Regul Aff. 2016;4(3):1-10. https://doi.org/10.22270/ijdra.v4i3.184
65. Cutler D, Kirson N, Long G. Financing drug innovation in the US: current framework and emerging challenges. PharmacoEconomics. 2020;38:905-11. https://doi.org/10.1007/s40273-020-00926-2
66. Barei F, Ross M. The refinement of the super generic concept: semantic challenge for product re-innovation? - GaBI J [Internet]. 2015;4(1):25-32 [cited 2024 Jul 9]. Available from: https://gabi-journal.net/the-refinement-of-the-super-generic-concept-semantic-challenge-for-product-re-innovation.html https://doi.org/10.5639/gabij.2015.0401.007
67. Who are the main competitors of Teva? [Internet]. [cited 2025 Jun 2]. Available from: https://synapse.patsnap.com/article/who-are-the-main-competitors-of-teva
68. TheGreySwan. Jan aushadhi and generics: is this a game changer for affordable healthcare? [Internet]. TheGreySwan; 2025 [cited 2025 Jun 2]. Available from: https://thegreyswan.substack.com/p/jan-aushadhi-and-generics-is-this
69. Medina JR, Cortes M, Romo E. Comparison of the Usp apparatus 2 and 4 for testing the in vitro release performance of ibuprofen generic suspensions. Int J Appl Pharm. 2017;9:90-5. https://doi.org/10.22159/ijap.2017v9i4.19926
70. Sowmya C, Abrar H, Prakaash K. Virtual bioequivalence in pharmaceuticals: current status and future prospects. Int J Appl Pharm. 2023;15:1-9. https://doi.org/10.22159/ijap.2023v15i5.48589
71. Ghabri S. Could or should we use cost-effectiveness thresholds in the French value-based pricing process for new drugs? PharmacoEconomics. 2024;42(8):823-7. https://doi.org/10.1007/s40273-024-01393-9
72. Das M, Choudhury S, Maity S, Hazra A, Pradhan T, Pal A, et al. Generic versus branded medicines: an observational study among patients with chronic diseases attending a public hospital outpatient department. J Nat Sci Biol Med. 2017;8(1):26. https://doi.org/10.4103/0976-9668.198351
Year
Month